Genmab ( (GMAB) ) has shared an update.
On March 4, 2025, Genmab A/S announced transactions involving shares and linked securities made by its managerial employees and their closely associated persons. The announcement detailed the vesting and net settlement of restricted stock units for key executives, including Jan van de Winkel and Anthony Pagano, which took place on March 3, 2025. These transactions are part of the company’s compliance with market abuse regulations, reflecting transparency in its operations and potentially impacting stakeholder perceptions of executive compensation practices.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark, primarily focused on the development of antibody therapeutics for the treatment of cancer. The company is listed on Nasdaq under the ticker GMAB.
YTD Price Performance: 8.00%
Average Trading Volume: 1,348,531
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.28B
See more data about GMAB stock on TipRanks’ Stock Analysis page.